Abstract
Recurrent respiratory papillomatosis (RRP) is a rare, benign disease with no known cure. RRP is caused by infection of the upper aerodigestive tract with the human papillomavirus (HPV). Passage through the birth canal is thought to be the initial transmission event, but infection may occur in utero. HPV vaccines have helped to provide protection from cervical cancer; however, their role in the prevention of RRP is undetermined. Clinical presentation of initial symptoms of RRP may be subtle. RRP course varies, and current management focuses on surgical debulking of papillomatous lesions with or without concurrent adjuvant therapy.
Copyright © 2012 Elsevier Inc. All rights reserved.
MeSH terms
-
Antiviral Agents / therapeutic use
-
Child
-
Delayed Diagnosis
-
Genome, Viral
-
Humans
-
Incidence
-
Interferon-alpha / therapeutic use
-
Laryngeal Mucosa / pathology
-
Laryngopharyngeal Reflux / etiology
-
Laryngopharyngeal Reflux / therapy
-
Laryngoscopy
-
Laser Therapy
-
Oncogene Proteins, Viral / physiology
-
Papilloma / diagnosis
-
Papilloma / economics
-
Papilloma / therapy*
-
Papilloma / virology*
-
Papillomaviridae
-
Papillomavirus Infections / complications*
-
Papillomavirus Infections / diagnosis
-
Papillomavirus Infections / economics
-
Papillomavirus Infections / transmission
-
Papillomavirus Vaccines
-
Photochemotherapy
-
Recurrence
-
Respiratory Tract Infections / diagnosis
-
Respiratory Tract Infections / economics
-
Respiratory Tract Infections / virology*
-
Respiratory Tract Neoplasms / diagnosis
-
Respiratory Tract Neoplasms / economics
-
Respiratory Tract Neoplasms / therapy*
-
Respiratory Tract Neoplasms / virology*
Substances
-
Antiviral Agents
-
Interferon-alpha
-
Oncogene Proteins, Viral
-
Papillomavirus Vaccines